AUG 23, 2019 6:27 AM PDT

New hope for children's brain cancer DIPG

New research published in Nature Communications provides insight on a potential treatment for an aggressive form of brain cancer called Diffuse Intrinsic Pontine Gliomas (DIPG) which usually affects children under 10. There is currently no standard of care for DIPG as the tumor that grows in the brain stem is inoperable; and while the number of patients affected in the U.S. is only approximately 300 annually, most patients do not survive more than a year after diagnosis.

The research comes from a collaboration between scientists at Yale University, University of Iowa, and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. It identifies a pathway that could disrupt the cellular process of DIPG.

DIPG develops in part because of a genetic mutation called PPM1D which affects cell growth and cell stress response. The team behind the study figured out a way to directly target PPM1D via the metabolite called NAD.

"This is really an amazing new way to attack this cancer. We found that the mutated gene PPM1D essentially sets the stage for its own demise," said senior author of the study, Michael Berens, Ph.D., a TGen Deputy Director, head of TGen's DIPG research.

"Our study's potential translational impact should lead to clinical trials and renewed hope for these families who face such a difficult diagnosis for their child," said co-senior author Charles Brenner, Ph.D., Chairman of Biochemistry at the University of Iowa.

Children diagnosed with DIPG typically do not live longer than a year after diagnosis. Photo: Pixabay

Their investigations arose because typical treatments for adult gliomas were not producing the desired results; this urged the researchers to look at the tumors from a new angle, focusing on their vulnerabilities and the role of PPM1D.

As Science Daily reports, the team discovered that “mutated PPM1D silences a gene called NAPRT, which is key to the production of the NAD metabolite. With NAPRT unavailable, the cell switches to another protein needed to create NAD called NAMPT. By using a drug that inhibits the production of NAMPT, researchers found they could essentially starve to death those cancer cells with the PPM1D mutation.”

Another senior author Ranjit Bindra, M.D., Ph.D., Associate Professor of Therapeutic Radiology at the Yale Cancer Center, commented on the hope that the discovery brings. "It is such a devastating disease, and we have been so stymied in our progress for new DIPG therapies. Many drugs have been tested with no success at all. These findings now offer new hope for children with this truly terrible disease," he said.

Sources: Science Daily, Nature Communications

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAR 18, 2020
Drug Discovery & Development
MAR 18, 2020
Drug Could Effectively Treat a Lethal Blood Cancer
A pricey drug, called tyrosine kinase inhibitor (TKI), is used to continuously treat the blood cancer Chronic Myeloid Le ...
APR 12, 2020
Cancer
APR 12, 2020
Understanding the link between obesity and breast cancer
A researcher from the James Graham Brown Cancer Center at the University of Louisville claims to have figured out the mo ...
APR 23, 2020
Cancer
APR 23, 2020
Dual Inhibition from One Chemotherapy
Acute Myeloid Leukemia, or AML, is an aggressive blood cancer with a poor 5-year prognosis. The primary targets of chemo ...
MAY 16, 2020
Cancer
MAY 16, 2020
Red Blood Cells: More than just an Oxygen Delivery Service
The human body is a complex network of systems that often interact and affect each other. Recent work shows that red blo ...
MAY 18, 2020
Cancer
MAY 18, 2020
How do Ohnologs affect Cancer?
Genetics can be complicated to say the least. Sometimes it can be as simple as a single mutation in one gene that causes ...
MAY 14, 2020
Drug Discovery & Development
MAY 14, 2020
Therapeutic for Gastrointestinal Tumors
The FDA has approved ripretinib (Qinlock) which is the first drug for fourth-line treatment of advanced gastrointestinal ...
Loading Comments...